RT Journal Article
SR Electronic
T1 The Cognitive, Age, Functioning, and Apolipoprotein E4 (CAFE) Scorecard to Predict the Development of Alzheimer’s Disease: A White-Box Approach
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.02.24311399
DO 10.1101/2024.08.02.24311399
A1 Wiranto, Yumiko
A1 Setiawan, Devin R
A1 Watts, Amber
A1 Ashourvan, Arian
A1 ,
YR 2024
UL http://medrxiv.org/content/early/2024/08/03/2024.08.02.24311399.abstract
AB Objective This study aimed to bridge the gap between the costliness and complexity of diagnosing Alzheimer’s disease by developing a scoring system with interpretable machine learning to predict the risk of Alzheimer’s using obtainable variables to promote accessibility and early detection.Participants and Methods We analyzed 713 participants with normal cognition or mild cognitive impairment from the Alzheimer’s Disease Neuroimaging Initiative. We integrated cognitive test scores from various domains, informant-reported daily functioning, APOE genotype, and demographics to generate the scorecards using the FasterRisk algorithm.Results Various combinations of 5 features were selected to generate ten scorecards with a test area under the curve ranging from 0.867 to 0.893. The best performance scorecard generated the following point assignments: age < 76 (-2 points); no APOE ε4 alleles (-3 points); Rey Auditory Verbal Learning Test <= 36 items (4 points); Logical Memory delayed recall <= 3 items (5 points); and Functional Assessment Questionnaire <= 2 (-5 points). The probable Alzheimer’s development risk was 4.3% for a score of -10, 31.5% for a score of -3, 50% for a score of -1, 76.3% for a score of 1, and greater than 95% for a score of > 6.Conclusions Our findings highlight the potential of these interpretable scorecards to predict the likelihood of developing Alzheimer’s disease using obtainable information, allowing for applicability across diverse healthcare environments. While our initial scope centers on Alzheimer’s disease, the foundation we have established paves the way for similar methodologies to be applied to other types of dementia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors have no funding to report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data that were originally located at https://adni.loni.usc.edu/)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData used in the analysis were obtained from 722 the Alzheimer’s Disease Neuroimaging Initiative 723 (ADNI) database (https://adni.loni.usc.edu/) https://adni.loni.usc.edu